Coherus’ Lucentis Biosimilar Outstrips Biogen Rival One Month After Launch
$100m In Cimerli Revenues Anticipated In 2023, Q Code Submitted
One month after launching its Cimerli ranibizumab biosimilar to Lucentis, Coherus BioSciences’ management explained how it had stolen a march on the earlier introduced Byooviz product launched by Biogen/Samsung Bioepis.
You may also be interested in...
Formycon has announced a June 2024 FDA action date for its FYB203 proposed aflibercept biosimilar rival to Eylea, which is due to be marketed by Coherus in the US.
Samsung Bioepis responded to Generics Bulletin enquiries following its EU-wide approval for a biosimilar to AstraZeneca’s Soliris.
Biogen has launched the Samsung Bioepis-developed Byooviz version of Lucentis in Canada, marking the first and only ranibizumab biosimilar to be approved and introduced in the market.